Approximately 20,000 hematopoietic cell transplantation (HCT) procedures are performed in the United States annually. With advances in transplantation technology and supportive care practices, HCT has become safer, and patient survival continues to improve over time. Indications for HCT continue to evolve as research refines the role for HCT in established indications and identifies emerging indications where HCT may be beneficial. The American Society for Blood and Marrow Transplantation (ASBMT) established a multiplestakeholder task force consisting of transplant experts, payer representatives, and a patient advocate to provide guidance on "routine" indications for HCT. This white paper presents the recommendations from the task force. Indications for HCT were categorized as follows: (1) Standard of care, where indication for HCT is well defined and supported by evidence; (2) Standard of care, clinical evidence available, where large clinical trials and observational studies are not available but HCT has been shown to be effective therapy; (3) Standard of care, rare indication, for rare diseases where HCT has demonstrated effectiveness but large clinical trials and observational studies are not feasible; (4) Developmental, for diseases where preclinical and/or early phase clinical studies show HCT to be a promising treatment option; and (5) Not generally recommended, where available evidence does not support the routine use of HCT. The ASBMT will periodically review these guidelines and will update them as new evidence becomes available. Ó
INTRODUCTION
Hematopoietic stem cell transplantation (HCT) using hematopoietic progenitor cells from the patient (autologous HCT) or a donor (allogeneic HCT) is a potentially curative therapy for many life-threatening cancers and nonmalignant disorders. Approximately 20,000 HCTs are performed in the United States each year [1] . The number of annual procedures is projected to increase because of several advancements in the field of HCT [2] , such as routine use of reduced-intensity conditioning regimens, which allows HCT in older patients who have a high incidence of hematologic malignancies; emerging indications for HCT; and introduction of alternative graft sources such that nearly all patients who need a transplant now have a donor. At the same time, early and long-term HCT outcomes continue to improve with significant improvements in patient selection for HCT, transplantation technology, and preventive and supportive care practices [3] [4] [5] [6] .
The American Society for Blood and Marrow Transplantation (ASBMT), in response to a need identified by patients, providers, payers, and policymakers, established a Task Force to provide guidance on indications for HCT, that is, which indications may be considered as routine care versus indications where evidence is emerging or insufficient. The Task Force consisted of clinical experts, payers, and patient advocates and was charged with providing consensus guidelines for clinically appropriate indications for HCT based on best prevailing evidence. This white paper presents the recommendations from the Task Force.
GENERAL PRINCIPLES
This article is intended to serve as a guide to the current consensus on the use of HCT to treat a specific indication, both within and external to the clinical trial setting. The Task Force emphasizes that the guidelines should not be used to determine whether HCT should be pursued as a treatment for an individual patient. Whether or not to proceed with transplantation in an individual patient is a clinical decision best made between the patient and his or her provider after a careful consideration of the alternatives, risks, and benefits of the procedure. The Task Force recognizes that most transplant centers have a regular forum (eg, tumor board or patient selection/care conference) where HCT as a treatment option for individual patients is discussed. However, this document may serve as a foundation for discussion among patients, providers, payers, and policymakers regarding coverage for HCT for specific indications.
The following guiding principles were followed by the Task Force in the development of these guidelines:
The medical decision-making process for a transplant procedure is complex and includes several factors besides the underlying indication for transplantation. Some examples of such variables include patient's overall health and performance status, comorbidities, disease risk/status (eg, remission state and responsiveness to treatment), and graft and donor source. Clinicians routinely consider such factors when evaluating a patient with a specific indication for HCT. Recommendations for some diagnoses consider disease risk (eg, cytogenetics inacute myeloid leukemia and acute lymphoblastic leukemia). Disease risk is not defined as a part of this guidance document, and clinicians are instead referred to other guidelines such as those proposed by the National Comprehensive Cancer Network (NCCN; www.nccn.org). For the purposes of these guidelines, the definition of HCT as proposed by the ASBMT and the National Marrow Donor Program/Be The Match was followed [7, 8] . HCT is defined as an episode of care starting with a preparative regimen and continuing through hematopoietic stem cell infusion and recovery. Hematopoietic stem cell infusion is the infusion of a product (bone marrow, peripheral blood stem cells, cord blood) that contains hematopoietic progenitor cells, often characterized by CD34 expression. The European Group for Blood and Marrow Transplantation (EBMT) and the British Society of Blood and Marrow Transplantation (BSBMT) have published recommendations for HCT indications [9, 10] . The EBMT and BSBMT guidelines were reviewed in the process of developing ASBMT guidelines. The Task Force considered a formal systematic evidence review of the literature but determined that it would not be feasible in the process of formulating our expansive guidelines. Clinical trials and observational studies generally focus on specific questions within a disease or a group of diseases (eg, comparing outcomes in a subset of patients with a disease or investigating approaches for preventing relapse and minimizing morbidity and mortality of transplantation). Extrapolating the evidence to broad indication categories would be challenging. In general, for indications categorized as "Standard of care," "Standard of care, clinical evidence available," or "Standard of care, rare indication" (see below), the level of evidence and consensus was comparable with NCCN category 2A recommendation ("Based upon lower-level evidence, there is uniform consensus that the intervention is appropriate") [11] . All NCCN recommendations are category 2A, unless otherwise noted. Where available, published systematic evidence reviews or guidelines were used as the basis for our recommendations for categorizing indications. The ASBMT has published evidence-based reviews for several indications (Table 1) Although the list is not exhaustive, the references highlight evidence that was partly used as the basis for our recommendations. The guidelines focus on generally agreed on indications for the HCT procedure itself and do not go into other specific aspects of transplantation considered to be Table 1 List of Evidence-Based Reviews Performed by the ASBMT
Review
Year Published
Acute myeloid leukemia in children [12] 2007 Acute myeloid leukemia in adults [13] 2008 Myelodysplastic syndrome [14] 2009 Follicular lymphoma [15] 2010 Diffuse large B cell lymphoma [16] 2011 Acute lymphoblastic leukemia in children [17] 2012 Acute lymphoblastic leukemia in adults [18] 2012 Multiple myeloma [19] 2015 Hodgkin lymphoma [20] 2015
Available at: www.asbmt.org/?page¼GuidelineStatements.
beyond the scope of this white paper. We do not provide recommendations on type of conditioning regimen, graft-versus-host disease prophylaxis regimen, donor source, and graft source or recommendations on use of post-HCT maintenance therapy for specific indications.
Readers are referred to other published systematic evidence reviews and guidelines for this information. The Task Force recommendations are not designed to define comprehensive insurance benefits for HCT. Another ASBMT white paper provides recommendations on defining a standard episode of care for HCT and provides guidance on a general approach to coverage for indications of HCT [8] . Our guidelines can complement the evidence review that payers conduct as part of their technology assessment to determine coverage policies. These guidelines will supplement the Referral Guidelines: Recommended Timing for Transplant Consultation, developed jointly by the ASBMT and National Marrow Donor Program/Be The Match [21] .
RARE DISEASES
Where sufficient evidence from large studies was not available (eg, rare diseases), nonanalytic studies and expert opinion were used, and the recommendations represent prevalent routine clinical practice for those indications. Rather than provide a long and evolving list of unique rare diseases, the indication tables show a concise categorical list together with selected unique diagnoses for which transplant is most frequently offered (Tables 2 and 3 ). It is recognized that there is a large number of rare disorders for which transplantation may be used, and the appropriateness of HCT may depend on the phenotype and the degree of progression of the disease in an individual patient. To address these scenarios in their entirety is beyond the scope of this report. Gathering additional data in these situations will be important to better understand the benefits and limits of transplantation. Towards this goal and when possible, multi-institutional studies will prove important, preferably in centers with expertise in assessing diseasespecific outcomes. For rare indications, providers are advised to discuss with individual patients the risks and benefits of the HCT procedure while considering the available literature and clinical experience.
DONOR AND GRAFT SOURCE IN PATIENT SELECTION FOR HCT
In the present era, a suitable donor source can be found for most patients who may benefit from HCT [22] . Several clinical factors have to be considered when determining the optimal donor and graft source for a given patient, including but not limited to underlying disease, disease stage, and the urgency with which transplantation needs to be pursued. For example, a specific donor and graft source may not be suitable for some patients (eg, umbilical cord blood is not recommended as a donor/graft source for patients with myelofibrosis unless pursued as part of a clinical trial). Although HLA-identical sibling donor remains the preferred donor source, survival after transplantation is comparable among patients receiving hematopoietic progenitor cells from HLA-identical sibling and matched unrelated donors for several diseases [23] [24] [25] [26] [27] [28] [29] [30] [31] . Similarly, studies show that survival after umbilical cord blood transplantation is similar to other graft sources, and emerging data demonstrate acceptable outcomes with haploidentical donor transplantation [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] .
The literature on donor and graft sources continues to evolve rapidly over time. With this background, the Task Force did not differentiate recommendations for transplant indications based on donor source (ie, related donor, unrelated donor, umbilical cord blood, or haploidentical donor) or graft source (ie, bone marrow, peripheral blood stem cells, or umbilical cord blood). This is in contrast to guidelines published by the EBMT and BSBMT. Nonetheless, the Task Force recognizes that donor and graft sources are important considerations when determining the risks and benefits of HCT for an individual patient.
AGE IN PATIENT SELECTION FOR HCT
Age by itself should not be a contraindication to transplantation in patients who may benefit from this procedure. Selected older patients with limited comorbidities and good functional status can safely receive HCT with a relatively low and acceptable risk of nonrelapse mortality [42] [43] [44] . Instead of chronologic patient age, evaluations such as functional status, HCT-specific comorbidity index score, EBMT risk score, and Pre-transplantation Assessment of Mortality risk score can assist in determining risks of nonrelapse mortality and transplant candidacy for individual patients.
DEFINITIONS FOR CLASSIFYING INDICATIONS
The definitions for categorizing indications for transplantation are presented below. Tables 2 and 3 list the recommendations for HCT in pediatric and adult diseases.
Standard of Care (S)
This category includes indications that are well defined and generally supported by evidence in the form of highquality clinical trials and/or observational studies (eg, through the CIBMTR or EBMT).
Standard of Care, Clinical Evidence Available (C)
This category includes indications for which large clinical trials and observational studies are not available. However, HCT has been shown to be an effective therapy with acceptable risk of morbidity and mortality in sufficiently large single-or multicenter cohort studies. HCT can be considered as a treatment option for individual patients after careful evaluation of risks and benefits. As more evidence becomes available, some indications may be reclassified as "S."
Standard of Care, Rare Indication (R)
Indications included in this category are rare diseases for which clinical trials and observational studies with sufficient number of patients are not currently feasible because of their very low incidence. However, single-or multicenter or registry studies in relatively small cohorts of patients have shown HCT to be effective treatment with acceptable risks of morbidity and mortality. For patients with diseases in this category, HCT can be considered as a treatment option for individual patients after careful evaluation of risks and benefits.
Developmental (D)
Developmental indications include diseases where preclinical and/or early phase clinical studies show HCT to be a promising treatment option. HCT is best pursued for these indications as part of a clinical trial. As more evidence becomes available, some indications may be reclassified as "C" or "S."
Not Generally Recommended (N)
Transplantation is not currently recommended for these indications where evidence and clinical practice do not support the routine use of HCT. The effectiveness of nontransplant therapies for an earlier phase of a disease does not justify the risks of HCT. Alternatively, a meaningful benefit is not expected from the procedure in patients with an advanced phase of a disease. However, this recommendation does not preclude investigation of HCT as a potential treatment, and transplantation may be pursued for these indications within the context of a clinical trial.
DATA REPORTING TO CIBMTR
US transplant centers report clinical and outcomes data on all allogeneic HCT procedures, and most centers report data on autologous HCT procedures to the CIBMTR. This data reporting and capture is critical to understanding appropriate indications for HCT and its utilization and patient outcomes.
PROCESS FOR UPDATING GUIDELINES
The Task Force recognizes the need for periodically updating these guidelines to keep abreast with ongoing research in the field. New evidence may result in inclusion of new indications not previously recognized or may lead to reclassification of recommendation category for an existing indication. The ASBMT's Practice Guidelines Committee will periodically review these guidelines and update them as necessary, with a minimum of once every 2 years.
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The draft manuscript was reviewed by the ASBMT's Practice Guidelines Committee and was posted on ASBMT's website for public comments. The document was modified based on feedback received by the ASBMT community.
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